<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04612907</url>
  </required_header>
  <id_info>
    <org_study_id>Hypo-M1 1.0</org_study_id>
    <nct_id>NCT04612907</nct_id>
  </id_info>
  <brief_title>Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer</brief_title>
  <acronym>Hypo-M1</acronym>
  <official_title>A Randomized Phase III, Multicenter Study to Evaluate Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Umeå University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Umeå University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      de Novo metastatic prostate cancer with limited metastatic spread benefits from local&#xD;
      radiotherapy to the prostate. Two different fractionation schedules will be tested.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with de Novo metastatic prostate cancer with limited disease spread has been shown&#xD;
      to gain benefit from local radiotherapy to the prostate. The internationally accepted&#xD;
      fractionation schedule is 3 Gy (Gray) x 19-20 over a course of 4 weeks.&#xD;
&#xD;
      There is continous evidence for even more hypo-fractionated radiotherapy with higher&#xD;
      fractionation doses. We will test if the schedule of 6.1Gy x 6 compares to standard of 3 Gy x&#xD;
      19 with regard to patient reported side-effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2028</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized to one of two treatment fractionations of radiotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity as scored by PROM (Patient Reported Outcome Measures) at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Acute toxicity score by PROM at eight weeks post radiotherapy. The mean PCSS (Prostate Cancer Symptom Scale) bother score for urinary tract will be measured. The primary outcome measurement will be the difference between mean values in the respective treatment arms measured at 8 weeks after end of radiotherapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity as scored by PROM at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Acute toxicity score by PROM at eight weeks post radiotherapy. The mean PCSS bother score for bowel will be measured. The primary outcome measurement will be the difference between mean values in the respective treatment arms measured at 8 weeks after end of radiotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Failure free survival</measure>
    <time_frame>12 months, 36 months</time_frame>
    <description>To evaluate the proportion of patients that are failure free at 12 and 36 months, failure free survival (FFS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Radiotherapy Side Effect</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>Moderate hypo-fractionation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiotherapy to the prostate delivered in 3Gy fractions x 19</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultra hypo-fractionation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy to the prostate delivered in 6.1Gy fractions x 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Moderate hypo-fractionation</intervention_name>
    <description>Patients will receive four weeks of radiotherapy</description>
    <arm_group_label>Moderate hypo-fractionation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Ultra-hypo-fractionation</intervention_name>
    <description>Patients will receive two and a half weeks of radiotherapy</description>
    <arm_group_label>Ultra hypo-fractionation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Informed Consent&#xD;
&#xD;
          2. Histological confirmed prostate cancer&#xD;
&#xD;
          3. Indication for early palliative radiation therapy of low burden metastatic prostate&#xD;
             cancer. Low burden as defined by modified CHAARTED trial criteria to maximum 4&#xD;
             skeletal mets at any site and/or any number of lymph nodes&#xD;
&#xD;
          4. baseline E-PROM&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. High burden metastatic prostate cancer including all with visceral mets.&#xD;
&#xD;
          2. Unable to comply with study procedures.&#xD;
&#xD;
          3. Other diseases or medication that will put the patient at risk for more toxicity from&#xD;
             radiotherapy&#xD;
&#xD;
          4. Radiation treatment start later than nine months after the prostate cancer diagnosis.&#xD;
&#xD;
          5. Severe micturition problems, IPSS &gt; 20 ( International Prostate Symptom Score)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Prostate cancer is a male disease</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Camilla of T Karlsson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancercentrum Umeå University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Camilla Thellenberg Karlsson, MD, PhD</last_name>
    <phone>+46 90 785 3296</phone>
    <email>camilla.thellenberg@umu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karin Söderkvist, MD, PhD</last_name>
    <phone>+4690 785 00 00</phone>
    <email>karin.soderkvist@umu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancercenter University hospital of Umeå</name>
      <address>
        <city>Umeå</city>
        <zip>90596</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Camilla Thellenberg Karlsson, MD, PhD</last_name>
      <phone>+46907853296</phone>
      <email>camilla.thellenberg@umu.se</email>
    </contact>
    <contact_backup>
      <last_name>Karin Söderkvist, MD, PhD</last_name>
      <phone>+46907850000</phone>
      <email>karin.soderkvist@umu.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 20, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic prostate cancer radiotherapy primary tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

